Lonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.
Source: FierceBiotech
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.